Taken together, we propose that NFE2L3 promotes CRC through changes in the tumor microenvironment, by suppressing the activity of Tregs and through the activation of mast cells, mediated, at least in part, via the increase of IL33 expression and decrease of RAB pathway signaling. The gene discussed is NFE2L3; the disease is colorectal carcinoma.